Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Publications

Prevalence and factors associated with multimorbidity among primary care patients with decreased renal function.

Hirst JA. et al, (2021), PLoS One, 16

A randomised controlled trial of a digital intervention for poorly controlled hypertension: Home and Online Management and Evaluation of Blood Pressure (HOME BP)

McManus R. et al, (2020), BMJ

Prevalence of chronic kidney disease in the community using data from OxRen: A UK population-based cohort study

Hirst JA. et al, (2020), British Journal of General Practice, 70, E285 - E293

Impact of a single eGFR and eGFR-estimating equation on chronic kidney disease reclassification: A cohort study in primary care

Hirst JA. et al, (2018), British Journal of General Practice, 68, e524 - e530

TELEMONITORING AND/OR SELF-MONITORING OF BLOOD PRESSURE IN HYPERTENSION (TASMINH4): A RANDOMISED CONTROLLED TRIAL

McManus R. et al, (2018), JOURNAL OF HYPERTENSION, 36, E5 - E5

Efficacy of self-monitored blood pressure, with or without telemonitoring, for titration of antihypertensive medication (TASMINH4): an unmasked randomised controlled trial

McManus RJ. et al, (2018), The Lancet, 391, 949 - 959

OPtimising Treatment for MIld Systolic hypertension in the Elderly (OPTiMISE): Protocol for a randomised controlled non-inferiority trial

Sheppard JP. et al, (2018), BMJ Open, 8

Telemonitoring and/or self-monitoring of blood pressure in hypertension (TASMINH4): Protocol for a randomised controlled trial

Franssen M. et al, (2017), BMC Cardiovascular Disorders, 17

Trastuzumab-associated cardiac events in the Persephone trial

Earl HM. et al, (2016), British Journal of Cancer, 115, 1462 - 1470

PERSEPHONE is a randomised phase III controlled trial comparing six months of trastuzumab to the standard 12 months in patients with HER2 positive early breast cancer

Earl H. et al, (2014), European Journal of Surgical Oncology, 40, 619 - 619

PERSEPHONE: Duration of Trastuzumab with Chemotherapy in women with HER2 positive early breast cancer

Earl HM. et al, (2012), CANCER RESEARCH, 72

OT1-02-08: The PERSEPHONE Trial: Duration of Trastuzumab with Chemotherapy in Women with HER2 Positive Early Breast Cancer. Changing the Randomisation Point To Address Potential Barriers to Recruitment.

Earl HM. et al, (2011), Ongoing Clinical Trials Poster Session Abstracts

Optimising patient recall of adverse events over prolonged time periods

Hiller L. et al, (2011), Trials, 12